Takeda's tetravalent dengue vaccine (TAK-003) receives first global approval for use in Indonesia without need for pre-vaccination testing | Asia Research News
CONTRIBUTING TO THE FIGHT AGAINST DENGUE
FDA grants priority review to Takeda's dengue vaccine – PharmaLive
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC
VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | 2 Minute Medicine
TAK-003
Takeda dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration - Headlines of Today
Takeda's dengue shot keeps 84% of kids out of hospital regardless of prior infection, giving it a leg up over Sanofi's Dengvaxia | Fierce Biotech
Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003) | PLOS Neglected Tropical Diseases
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC
Takeda's dengue vaccine TAK-003 shows efficacy through 4.5 years in trial | Seeking Alpha
Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003) | PLOS Neglected Tropical Diseases
Global First Approval For Takeda's Dengue Vaccine, In Indonesia :: Scrip
Takeda Dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial
TAK-003 induces functional DENV cross-reactive cellular immmunity | Immunopaedia
PharmaShots. - • The submission is based on a P-III TIDES trial assessing TAK-003 (0.5ml, SC) vs PBO in 20,000+ healthy children & adolescents aged 4-16yrs. to prevent dengue fever of any
wave1presentation Foreign Issuer Report 6-K
Cross-reactivity of T cell responses following TAK-003... | Download Scientific Diagram
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | NEJM
Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
TAK-003 vaccine: Trial shows Continued Protection against Dengue Fever - YouTube
Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial - The Lancet
